The US Court of Appeals for the Federal Circuit remanded the case to the Patent Trial and Appeal Board to consider patent validity.

The agreement will enable Beijing-based RocGene to distribute its qPCR systems, reagents, and consumables in South Korea and to explore additional market strategies.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The agency cleared lab-based and point-of-care infectious disease and clinical chemistry tests as well as software for digital pathology.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The analyzer is designed to provide extended differential and rapid C-reactive protein whole blood measurement.

The firm's benchtop TruVerus system can now run a total of 26 FDA-cleared assays in three modalities from a single blood collection tube.

The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.